What have we learned from ICON1 and ACTION?

N. Colombo, Sergio Pecorelli

Research output: Contribution to journalArticle

Abstract

Still, 20-30% of women with early-stage ovarian cancer eventually die from their disease. Adequate treatment for this subset of patients has not yet been identified, the greatest dispute being about the role of adjuvant therapy after surgical staging. No randomized trial has reliably demonstrated a survival advantage for one of the many approaches over another or over careful observation without immediate further adjuvant therapy. A combined analysis of two parallel randomized clinical trials in early ovarian cancer, ICON 1 and ACTION, comparing platinum-containing adjuvant chemotherapy to observation following surgery was performed, with survival as primary end point and time to recurrence as a secondary one. A total of 924 patients were randomized. With over 4 years median follow up for survivors, the hazard ratio for recurrence-free survival is 0.64 (95% CI, 0.50-0.82; P=0.001) in favor of adjuvant chemotherapy, with an absolute difference of 11%. For overall survival, the hazard ratio is 0.67 (95% CI, 0.50-0.90; P = 0.008) in favor of adjuvant chemotherapy. These results translate into an absolute difference of 8% in the adjuvant chemotherapy group and indicate that adjuvant platinum-containing chemotherapy improves the survival and disease-free survival. Sub-group analysis demonstrated in the ACTION trial that completeness of surgical staging was an independent factor for prognosis, both for progression-free and for overall survival (along with histological type and tumor grade), while in suboptimally staged patients, adjuvant chemotherapy did improve the outcome.

Original languageEnglish
Pages (from-to)140-143
Number of pages4
JournalInternational Journal of Gynecological Cancer
Volume13
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Adjuvant Chemotherapy
Survival
Platinum
Ovarian Neoplasms
Disease-Free Survival
Observation
Recurrence
Dissent and Disputes
Survivors
Therapeutics
Randomized Controlled Trials
Drug Therapy
Neoplasms

Keywords

  • Adjuvant treatment
  • Early ovarian cancer
  • Surgical staging

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynaecology
  • Oncology

Cite this

What have we learned from ICON1 and ACTION? / Colombo, N.; Pecorelli, Sergio.

In: International Journal of Gynecological Cancer, Vol. 13, No. SUPPL. 2, 11.2003, p. 140-143.

Research output: Contribution to journalArticle

Colombo, N. ; Pecorelli, Sergio. / What have we learned from ICON1 and ACTION?. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. SUPPL. 2. pp. 140-143.
@article{939793b829394e1784dcc4949e589b8e,
title = "What have we learned from ICON1 and ACTION?",
abstract = "Still, 20-30{\%} of women with early-stage ovarian cancer eventually die from their disease. Adequate treatment for this subset of patients has not yet been identified, the greatest dispute being about the role of adjuvant therapy after surgical staging. No randomized trial has reliably demonstrated a survival advantage for one of the many approaches over another or over careful observation without immediate further adjuvant therapy. A combined analysis of two parallel randomized clinical trials in early ovarian cancer, ICON 1 and ACTION, comparing platinum-containing adjuvant chemotherapy to observation following surgery was performed, with survival as primary end point and time to recurrence as a secondary one. A total of 924 patients were randomized. With over 4 years median follow up for survivors, the hazard ratio for recurrence-free survival is 0.64 (95{\%} CI, 0.50-0.82; P=0.001) in favor of adjuvant chemotherapy, with an absolute difference of 11{\%}. For overall survival, the hazard ratio is 0.67 (95{\%} CI, 0.50-0.90; P = 0.008) in favor of adjuvant chemotherapy. These results translate into an absolute difference of 8{\%} in the adjuvant chemotherapy group and indicate that adjuvant platinum-containing chemotherapy improves the survival and disease-free survival. Sub-group analysis demonstrated in the ACTION trial that completeness of surgical staging was an independent factor for prognosis, both for progression-free and for overall survival (along with histological type and tumor grade), while in suboptimally staged patients, adjuvant chemotherapy did improve the outcome.",
keywords = "Adjuvant treatment, Early ovarian cancer, Surgical staging",
author = "N. Colombo and Sergio Pecorelli",
year = "2003",
month = "11",
doi = "10.1111/j.1525-1438.2003.13366.x",
language = "English",
volume = "13",
pages = "140--143",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - What have we learned from ICON1 and ACTION?

AU - Colombo, N.

AU - Pecorelli, Sergio

PY - 2003/11

Y1 - 2003/11

N2 - Still, 20-30% of women with early-stage ovarian cancer eventually die from their disease. Adequate treatment for this subset of patients has not yet been identified, the greatest dispute being about the role of adjuvant therapy after surgical staging. No randomized trial has reliably demonstrated a survival advantage for one of the many approaches over another or over careful observation without immediate further adjuvant therapy. A combined analysis of two parallel randomized clinical trials in early ovarian cancer, ICON 1 and ACTION, comparing platinum-containing adjuvant chemotherapy to observation following surgery was performed, with survival as primary end point and time to recurrence as a secondary one. A total of 924 patients were randomized. With over 4 years median follow up for survivors, the hazard ratio for recurrence-free survival is 0.64 (95% CI, 0.50-0.82; P=0.001) in favor of adjuvant chemotherapy, with an absolute difference of 11%. For overall survival, the hazard ratio is 0.67 (95% CI, 0.50-0.90; P = 0.008) in favor of adjuvant chemotherapy. These results translate into an absolute difference of 8% in the adjuvant chemotherapy group and indicate that adjuvant platinum-containing chemotherapy improves the survival and disease-free survival. Sub-group analysis demonstrated in the ACTION trial that completeness of surgical staging was an independent factor for prognosis, both for progression-free and for overall survival (along with histological type and tumor grade), while in suboptimally staged patients, adjuvant chemotherapy did improve the outcome.

AB - Still, 20-30% of women with early-stage ovarian cancer eventually die from their disease. Adequate treatment for this subset of patients has not yet been identified, the greatest dispute being about the role of adjuvant therapy after surgical staging. No randomized trial has reliably demonstrated a survival advantage for one of the many approaches over another or over careful observation without immediate further adjuvant therapy. A combined analysis of two parallel randomized clinical trials in early ovarian cancer, ICON 1 and ACTION, comparing platinum-containing adjuvant chemotherapy to observation following surgery was performed, with survival as primary end point and time to recurrence as a secondary one. A total of 924 patients were randomized. With over 4 years median follow up for survivors, the hazard ratio for recurrence-free survival is 0.64 (95% CI, 0.50-0.82; P=0.001) in favor of adjuvant chemotherapy, with an absolute difference of 11%. For overall survival, the hazard ratio is 0.67 (95% CI, 0.50-0.90; P = 0.008) in favor of adjuvant chemotherapy. These results translate into an absolute difference of 8% in the adjuvant chemotherapy group and indicate that adjuvant platinum-containing chemotherapy improves the survival and disease-free survival. Sub-group analysis demonstrated in the ACTION trial that completeness of surgical staging was an independent factor for prognosis, both for progression-free and for overall survival (along with histological type and tumor grade), while in suboptimally staged patients, adjuvant chemotherapy did improve the outcome.

KW - Adjuvant treatment

KW - Early ovarian cancer

KW - Surgical staging

UR - http://www.scopus.com/inward/record.url?scp=1242275170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242275170&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2003.13366.x

DO - 10.1111/j.1525-1438.2003.13366.x

M3 - Article

C2 - 14656270

AN - SCOPUS:1242275170

VL - 13

SP - 140

EP - 143

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - SUPPL. 2

ER -